Ruchit Jain of Motilal Oswal recommended buying Zydus Lifesciences citing pharma sector relative strength

Tue 29 Sep 2026

Stop loss

1180

Target price

1270

Heard on Live TV News Channel between 08:59:57 - 09:01:12 IST.

• Analyst noted pharma and IT were the least corrective sectors in the previous session, with pharma showing good relative strength.
• Zydus Lifesciences technically looks strong within the pharma space with room on the upside.
• Recommended buying with stop loss below 1,180 for target around 1,270.

The call above is Ruchit Jain, Motilal Oswal Financial Services's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.